| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
T and B Cells with Subsets
MessageSendout, Mayo test code: TBBS
Test Code
LAB5210344
Alias/See Also
Quantitative Lymphocyte Subsets
T, B, and NK, B-Cell
Helper Suppressor Ratio
Immune Competence
T cell
Quant CD4 and CD8
Natural Killer Cells
TBBS
T, B, and NK, B-Cell
Helper Suppressor Ratio
Immune Competence
T cell
Quant CD4 and CD8
Natural Killer Cells
TBBS
CPT Codes
86355, 86357, 86359, 86360
Preferred Specimen
3 mL whole fblood from lavender EDTA tube
Minimum Volume
1 mL
Other Acceptable Specimens
Pink EDTA tube
Instructions
For serial monitoring, it is recommended that specimen collection be performed at the same time of day.
Transport Container
Original tube
Transport Temperature
Ambient
Specimen Stability
Ambient: 52 hours
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis: Mild OK; Gross reject
Lipemia: Mild OK; Gross reject
Other ACD or heparin blood, specimen in aliquot tube
Lipemia: Mild OK; Gross reject
Other ACD or heparin blood, specimen in aliquot tube
Methodology
Flow Cytometry
FDA Status
Approved
Setup Schedule
Monday through Sunday
Report Available
1-2 days
Limitations
Lymphocyte subset counts should be appropriately interpreted in context of the clinical presentation and other immunological parameters and relevant laboratory test results.
For serial monitoring of lymphocyte subsets, it is recommended that the patient be evaluated at the same time of the day to account for diurnal variation.
For follow-up of infants identified by newborn screening for severe combined immunodeficiency (SCID) and severe T-cell lymphopenia, SCID should be considered as a potential diagnosis in infants with fewer than 300 autologous CD3 T cells/mcL. Infants with 300 to 1500 autologous CD3 T cells/mcL may have leaky SCID, Omenn syndrome, or variant SCID, depending on other clinical and molecular features.
In infants identified by newborn screening for SCID, T-cell lymphopenia is defined as having up to 1500 autologous CD3 T cells/mcL.
This assay should not be used for diagnosing lymphocytic malignancies or evaluation of lymphocytosis of unknown etiology, though the latter may be identified through this assay in a screening assessment. In such cases, LCMS / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Varies will be recommended, which includes a hematopathology review. However, this assay can be used for absolute quantitation of B cells in CLL patients.
For serial monitoring of lymphocyte subsets, it is recommended that the patient be evaluated at the same time of the day to account for diurnal variation.
For follow-up of infants identified by newborn screening for severe combined immunodeficiency (SCID) and severe T-cell lymphopenia, SCID should be considered as a potential diagnosis in infants with fewer than 300 autologous CD3 T cells/mcL. Infants with 300 to 1500 autologous CD3 T cells/mcL may have leaky SCID, Omenn syndrome, or variant SCID, depending on other clinical and molecular features.
In infants identified by newborn screening for SCID, T-cell lymphopenia is defined as having up to 1500 autologous CD3 T cells/mcL.
This assay should not be used for diagnosing lymphocytic malignancies or evaluation of lymphocytosis of unknown etiology, though the latter may be identified through this assay in a screening assessment. In such cases, LCMS / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Varies will be recommended, which includes a hematopathology review. However, this assay can be used for absolute quantitation of B cells in CLL patients.
Reference Range
Included with report
Clinical Significance
Serial monitoring of CD4 T-cell count in patients who are HIV-positive
Follow-up and diagnostic evaluation of primary immunodeficiencies, including severe combined immunodeficiency
Immune monitoring following immunosuppressive therapy for transplantation, autoimmunity, and other immunological conditions where such treatment is utilized
Assessment of immune reconstitution post hematopoietic cell transplantation
Early screening of gross quantitative anomalies in lymphocyte subsets in infection or malignancies
Absolute quantitation of circulating B cells for diagnosis of patients with chronic lymphocytic leukemia as indicated in the 2008 International Workshop on Chronic Lymphocytic Leukemia guidelines
Follow-up and diagnostic evaluation of primary immunodeficiencies, including severe combined immunodeficiency
Immune monitoring following immunosuppressive therapy for transplantation, autoimmunity, and other immunological conditions where such treatment is utilized
Assessment of immune reconstitution post hematopoietic cell transplantation
Early screening of gross quantitative anomalies in lymphocyte subsets in infection or malignancies
Absolute quantitation of circulating B cells for diagnosis of patients with chronic lymphocytic leukemia as indicated in the 2008 International Workshop on Chronic Lymphocytic Leukemia guidelines
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Quantitative Lymphocyte Subsets: T, B, and Natural Killer (NK) Cells, Blood
